Published in J Virol on July 17, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front Oncol (2014) 0.93
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology (2015) 0.77
Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. J Virol (2017) 0.75
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer (1981) 3.90
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci U S A (1986) 2.45
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem (2001) 2.41
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene (2010) 1.99
Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem (1995) 1.95
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest (2011) 1.80
The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res (2008) 1.75
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles. Virology (2001) 1.68
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res (2002) 1.66
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology (2002) 1.64
Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res (1998) 1.59
Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J Virol (2006) 1.53
Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol (1995) 1.52
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res (2011) 1.43
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol (2008) 1.38
Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci (1998) 1.37
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr (2013) 1.31
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie (2009) 1.28
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol (2009) 1.28
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27
Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem (2002) 1.27
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry. J Virol (2009) 1.25
Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem (1993) 1.25
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Inhibitory effects of human and bovine milk constituents on rotavirus infections. J Dairy Sci (2004) 1.23
Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res (2004) 1.23
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2007) 1.19
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2008) 1.17
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 1.16
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2010) 1.15
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 1.15
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther (2010) 1.08
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res (2003) 1.08
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol (2009) 1.06
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol (2008) 1.02
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 1.00
Leukotrienes play protective roles early during experimental VSV encephalitis. J Neuroimmunol (2001) 0.98
Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology (2008) 0.98
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther (2010) 0.95
Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther (2011) 0.94
Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev (2010) 0.93
Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology (2007) 0.92
Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg (2007) 0.92
Antiviral activity of purified human breast milk mucin. Neonatology (2007) 0.89
MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol (2006) 0.89
Organ-specific pancreatic tumor growth properties and tumor immunity. Cancer Immunol Immunother (1999) 0.88
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol (2011) 0.88
PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol (2013) 0.87
Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer (2007) 0.87
Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J Urol (2010) 0.87
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer (2008) 0.86
Mucins and pancreatic cancer. Cancers (Basel) (2010) 0.85
VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther (2009) 0.84
Pancreatic cancer - cost for overtreatment with gemcitabine. Acta Oncol (2012) 0.84
Electrochemical sensing of aptamer-facilitated virus immunoshielding. Anal Chem (2012) 0.83
Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) (2012) 0.83
The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol (2012) 0.81
Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc Natl Acad Sci U S A (2003) 2.43
Bridging the inferential gap: the electronic health record and clinical evidence. Health Aff (Millwood) (2007) 1.81
Medical homes: challenges in translating theory into practice. Med Care (2009) 1.69
What do resident physicians know about nutrition? An evaluation of attitudes, self-perceived proficiency and knowledge. J Am Coll Nutr (2008) 1.59
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res (2009) 1.57
Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res (2011) 1.43
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol (2008) 1.38
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
The New York State cardiac registries: history, contributions, limitations, and lessons for future efforts to assess and publicly report healthcare outcomes. J Am Coll Cardiol (2012) 1.31
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res (2009) 1.25
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res (2006) 1.24
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol (2004) 1.21
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res (2005) 1.21
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res (2004) 1.18
Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin Ther (2011) 1.17
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways. Mol Cancer Res (2006) 1.09
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol (2006) 1.09
A randomized controlled trial of a multilevel intervention to increase colorectal cancer screening among Latino immigrants in a primary care facility. J Gen Intern Med (2010) 1.07
Uses of electronic health records for public health surveillance to advance public health. Annu Rev Public Health (2015) 1.07
Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology (2003) 1.07
Strategies for implementing and sustaining therapeutic lifestyle changes as part of hypertension management in African Americans. Postgrad Med (2009) 1.07
Housing as health care--New York's boundary-crossing experiment. N Engl J Med (2013) 1.06
Validation of the Spanish translation of the Patient Assessment of Chronic Illness Care (PACIC) survey. Prev Chronic Dis (2008) 1.01
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol (2003) 0.99
Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology (2010) 0.97
Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. Gastroenterology (2006) 0.96
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol Immunother (2014) 0.96
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer (2011) 0.95
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients. Thromb Haemost (2004) 0.95
Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice. Plant Biotechnol J (2011) 0.95
The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol (2013) 0.94
RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. Glia (2010) 0.93
Cellular FLIP can substitute for the herpes simplex virus type 1 latency-associated transcript gene to support a wild-type virus reactivation phenotype in mice. J Neurovirol (2008) 0.93
Shared decision making: using health information technology to integrate patient choice into primary care. Transl Behav Med (2011) 0.92
Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow. Cancer Res (2009) 0.91
Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer (2014) 0.91
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) (2012) 0.88
Morel-lavallée lesion in a professional american football player. Am J Orthop (Belle Mead NJ) (2010) 0.88
Non-insertional tendinopathy of the subscapularis. Int J Shoulder Surg (2013) 0.86
Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach. Virol J (2009) 0.86
Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Res (2013) 0.85
Pinch and elbow extension restoration in people with tetraplegia: a systematic review of the literature. J Hand Surg Am (2009) 0.84
The wired patient: patterns of electronic patient portal use among patients with cardiac disease or diabetes. J Med Internet Res (2015) 0.83
Identification of sendai virus L protein amino acid residues affecting viral mRNA cap methylation. J Virol (2008) 0.83
Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother (2012) 0.82
Meaningful use in practice using patient-specific risk in an electronic health record for shared decision making. Am J Prev Med (2011) 0.82
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine (2007) 0.81
Donor heart preservation with pinacidil: the role of the mitochondrial K ATP channel. Ann Thorac Surg (2004) 0.81
Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clin Dev Immunol (2009) 0.81
The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. J Clin Epidemiol (2005) 0.80
Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers. Antivir Ther (2010) 0.79
Appropriateness of statins in patients aged ≥80 years and comparison to other age groups. Am J Cardiol (2012) 0.79
Progress towards a more physiologic approach to donor heart preservation: the advantages of hyperpolarized arrest. J Heart Lung Transplant (2005) 0.79
Sequence-function analysis of the Sendai virus L protein domain VI. Virology (2010) 0.79
Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. J Interferon Cytokine Res (2013) 0.79
Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model. Cancer Immunol Immunother (2010) 0.78
Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res (2002) 0.78
Redesigning the regulatory framework for ambulatory care services in New York. Milbank Q (2014) 0.77
Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer. Pancreas (2015) 0.76
Detecting protein-protein interactions in vesicular stomatitis virus using a cytoplasmic yeast two hybrid system. J Virol Methods (2011) 0.76
Utility of different lipid measures to predict coronary heart disease. JAMA (2008) 0.75
Angiotensin and renal disease: the jury is still out. Am J Kidney Dis (2007) 0.75
NYSTEM: igniting a thriving stem cell research community. Stem Cells Transl Med (2013) 0.75
Literature search parameters marginally improved the pooled estimate accuracy for ultrasound in detecting deep venous thrombosis. J Clin Epidemiol (2006) 0.75
Biomarkers for prediction of cardiovascular events. N Engl J Med (2007) 0.75
Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer (2003) 0.75
What price pain relief? Circulation (2006) 0.75
Low-molecular-weight heparin for pulmonary embolism. Ann Intern Med (2004) 0.75
Metrics for evaluating the utility of patient-centered decision tools. Arch Intern Med (2010) 0.75
Low Internet use among patients with diabetes in a safety-net population. AMIA Annu Symp Proc (2007) 0.75
Integrating public health education in a public health practice setting: the experience of the School of Public Health, University at Albany and the New York State Department of Health. J Public Health Manag Pract (2014) 0.75
Unlocking the Power of Open Health Data: A Checklist to Improve Value and Promote Use. J Public Health Manag Pract (2017) 0.75
Experimental deerpox infection in black-tailed deer (Odocoileus hemionus columbianus). J Wildl Dis (2010) 0.75
Managing the human toll caused by seasonal influenza: New York State's mandate to vaccinate or mask. JAMA (2013) 0.75
Breast cancer from oral and transdermal estradiol: a cohort study of Finnish women. Womens Health (Lond Engl) (2007) 0.75
New York State Department of Health: approaching the documentation selection process from an improvement perspective. J Public Health Manag Pract (2013) 0.75